![caverject vs edex caverject vs edex](https://canadaonlinehealth.com/wp-content/uploads/2020/01/Synthroid-112mcg-CanadaOnlineHealth.png)
Therefore, this new treatment for ED can be offered to patients and could help address the needs unmet by other treatments.Įrectile dysfunction (ED) is a common disorder, with increasing incidence in men over 40 years of age. Its fast onset of action and lack of interactions with other drugs makes alprostadil cream a possible first-line therapeutic option for some patients with ED: individuals who are reluctant to take systemic treatments or have AEs, patients who do not respond, cannot tolerate, or do not accept PDE5 inhibitor therapy, and patients treated with nitrates.
![caverject vs edex caverject vs edex](http://images.rxlist.com/images/rxlist/caverject-impulse12.gif)
Clinical efficacy has been demonstrated in both phase II and III trials, showing a global efficacy up to 83% with the 300 μg dose in patients with severe ED, significantly better than placebo. Systemic AEs are reported in only 3% of the treated population. Alprostadil has a favourable pharmacodynamic profile and is poorly absorbed in systemic circulation, which makes it suitable in a lot of circumstances and results in a reduced risk of adverse effects (AEs).
Caverject vs edex skin#
It is now available in the form of a cream (Vitaros/Virirec), a noninvasive treatment which combines an active drug (alprostadil, a synthetic prostaglandin E1) with a skin enhancer improving its local absorption directly at the site of action. Alprostadil, a prostaglandin, has been marketed for many years as a urethral stick and an intracavernous injection for the treatment of ED. Several options are available for treating ED: oral pharmacotherapy with phosphodiesterase 5 (PDE5) inhibitors currently represents the first-line option for many patients with ED. Erectile dysfunction (ED) is a very common disorder with a deep impact on quality of life on both patients and partners.